Listed numerous times as one of America’s “Top Doctors” by Castle Connolly, Mortimer is the Baum Family Professor in Women’s Cancers. She takes a special interest in examining how hormones affect normal and tumor cells.

Harlan Levine, M.D., is president of strategy and business ventures for City of Hope. In this role, he is accountable for strategy, innovation and growth, drug commercialization, payer strategies and the Center for International Medicine. He also serves as the chairman of the board of AccessHope, City of Hope’s subsidiary focused on serving the employer market and making leading-edge cancer care available to all regardless of geography.

Malkas, the M.T.; B.A. Ahmadinia Professor in Molecular Oncology, focuses on how to create therapies to thwart cancer at the molecular level. She developed a therapy against neuroblastoma, a children’s cancer, which will soon be tested in a clinical trial.

Forman has been at the forefront of this exciting work for over 40 years and has been instrumental in increasing survival rates of patients with blood cancers during that time. He leads City of Hope’s innovative CAR T program.

Budde is investigating the use of CAR T cells to treat blood cancers and other diseases. She leads CAR T clinical trials. She is fluent in Mandarin.

Kwak, the Dr. Michael Friedman Professor in Translational Medicine, has pioneered breakthrough innovations in immunology and cancer vaccines, earning him a spot on TIME magazine’s 2010 100 most influential people in the world. Kwak recently served on the Food and Drug Administration advisory panel for the first approved CAR T cell therapy.

Badie, The Heritage Provider Network Professor in Gene Therapy, has performed thousands of brain surgeries and leads groundbreaking research into CAR T cell therapy for glioblastoma, publishing a case study in the New England Journal of Medicine.

George Bernard Semeniuk, III, M.D., was drawn to cancer care while in medical school, after a young family member died of brain cancer. More than two decades into his career in oncology, he strives to help each patient achieve the best possible outcome with an individualized treatment plan based on the understanding that each patient, and each family, is unique. As a patient of Dr. Semeniuk, you can expect to be greeted with a caring and compassionate attitude. You will get his undivided attention during your appointment. He works directly with your other providers to coordinate a personalized treatment plan that coincides with your values and goals. His practice focuses on head and neck, lung and skin cancers, and he works in conjunction with researchers at City of Hope to pioneer clinical research that focuses on various anti-cancer drug therapies in various phases of development. Dr. Semeniuk is trained in integrative oncology and combines complementary therapies with mainstream oncology care to address patients' physical, psychological and spiritual needs. After earning his M.D. at St. George's University in New York, Dr. Semeniuk was an intern and resident in internal medicine at the University of California San Francisco where he served as chief resident, a fellow in oncology/hematology at University of Texas Southwestern Medical Center and a fellow in integrative medicine at the University of Arizona. Before City of Hope, he maintained a longstanding private practice and held positions at Hoag Memorial Hospital Presbyterian and Keck School of Medicine of USC. Away from the clinic, Dr. Semeniuk enjoys golf, tennis, hiking, cooking and having new adventures with his family.

As deputy director of the T Cell Therapeutics Research Laboratory, Christine Brown, Ph.D., The Heritage Provider Network Professor in Immunotherapy, provides scientific oversight for the preclinical research program, as well as the ongoing clinical trial program focused on the development of CAR-engineered T cells for the treatment of hematological malignancies and solid tumors.

Wang is a research professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope. She researches immunotherapy, including vaccines, as well as CAR T cell therapy in multiple myeloma, non-Hodgkin’s lymphoma and acute lymphocytic leukemia.

As assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation and associate director of translational sciences in the T Cell Therapeutics Research Laboratory, Priceman is a principal investigator and provides scientific oversight on solid tumor immunotherapy programs focused on the development of CAR-engineered T cells and rational combination approaches for prostate cancer, breast cancer brain metastasis, ovarian cancer, pancreatic cancer and other solid tumor types.

Kandeel, the Arthur D. Riggs Distinguished Chair in Diabetes & Metabolism Research, is the principal investigator on the islet transplantation trial to determine the safety and efficacy of islet cell transplantation as a treatment for patients with type 1 diabetes.

A pioneer both in the operating room and in the laboratory, Yuman Fong, M.D., the Sangiacomo Family Chair in Surgical Oncology, is one of the most innovative surgeons in the world for liver cancer and has developed numerous new surgical techniques and instruments.

Gene therapy pioneer Zaia serves as the director of City of Hope’s Center for Gene Therapy. Zaia, the Aaron D. Miller and Edith Miller Chair in Gene Therapy, is internationally known and respected for his groundbreaking research into potential gene therapy treatments for HIV.

Tristan Scott, Ph.D., is an assistant research professor within the Center for Gene Therapy at City of Hope. He obtained his Ph.D. in molecular medicine and hematology, with an accompanying postdoctoral fellowship at the University of the Witwatersrand. His research has primarily focused on developing and applying protein- and RNA-guided technologies, including RNA interference, CRISPR/Cas and Zinc-finger technology for gene therapy applications toward infectious agents and cancers driven by viral agents. He has also developed various "classic" gene replacement or precision gene-editing cure approaches for hereditary diseases. He has explored a wide range of biological delivery systems, such as adeno-associated viruses, lentiviral vectors, lipid nanoparticles and extracellular vesicles for gene delivery. The overall focus of his research is the development of novel cellular and gene therapies against viral pathogens and inherited disorders with a significant global health burden.

Stacy Gray, M.D., serves on the ASCO Cancer Research Committee, holds multiple leadership roles in a National Institutes of Health research consortium and has presented her research both nationally and internationally. She has numerous peer-reviewed publications in such journals as Journal of Clinical Oncology, Journal of the National Cancer Institute, Journal of Oncology Practice, and Genetics in Medicine.

A practicing hematologist, Joseph Alvarnas, M.D., vice president for government affairs, speaks frequently to government officials and media about the future of chimeric antigen receptor (CAR) T therapies and costs. He is fluent in Spanish.

Herrera leads several clinical trials evaluating immune checkpoint inhibitors and other novel agents for the treatment of relapsed or refractory non-Hodgkin’s lymphoma or classical Hodgkin’s lymphoma and in lymphoma patients undergoing hematopoietic stem cell transplantation. He has published over 40 articles in peer-reviewed publications, abstracts and book chapters, and has been invited to present his work nationally and internationally.

Htut is determined to find more effective treatments for multiple myeloma, a rare blood cancer which strikes about 30,000 Americans each year. Htut is conducting multiple clinical trials examining immunotherapy options for myeloma.

Outgoing president of the American Association of Cancer Research, Caligiuri is the Deana and Steve Campbell Physician- in-Chief Distinguished Chair and is recognized for his work in immunology, specifically the use of human natural killer cells. More than 1,000 cancer patients have been treated in clinical trials developed or co-developed by Caligiuri.

Dadwal who has been with City of Hope since 2005 leads the Division of Infectious Diseases. He specializes in treating cancer patients who develop infections, a frequent complication of chemotherapy and transplants.

Sumanta Kumar Pal, M.D., is an internationally recognized leader in the area of genitourinary cancers. He is the co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease team at the institution.

Raz, who joined City of Hope in 2012, specializes in esophageal and lung cancer surgery and in raising public awareness about cancer risks.

Salgia leads groundbreaking research on lung cancer biology with the goal of finding better treatment options. He heads oncology and is the Arthur & Rosalie Kaplan Chair in Medical Oncology.

Leo Wang, M.D., Ph.D., attends on the pediatric oncology and stem cell transplant services while maintaining an active research laboratory. His research focuses on utilizing novel mass spectrometry-based phosphoproteomic techniques to identify targetable activation pathways in small numbers of rare cells.

Tanya Dorff, M.D., is a medical oncologist and professor in the Department of Medical Oncology & Therapeutics Research. As the head of the Genitourinary Cancers Program at City of Hope, Dr. Dorff is an internationally recognized leader in prostate cancer and is renowned for her work in other genitourinary tumor types, including kidney, bladder and penile cancer. Dr. Dorff leads City of Hope’s joint effort with the Prostate Cancer Foundation to develop novel immune-based chimeric antigen receptor (CAR) T cells that are primed to target prostate cancer tissue.

At City of Hope, Seewaldt, the Ruth Ziegler Chair in Population Sciences, leads community outreach education efforts to provide breast cancer education, free breast cancer screenings and treatment, mentorship of young minority scholars, and a forum for community partnered trials.

Wong’s primary areas of research include the development of novel strategies and agents for image-guided and biologically targeted radiation therapy for patients with locoregional and systemic disease.

Terence M. Williams, M.D., Ph.D., joins City of Hope as a professor and chair of the Department of Radiation Oncology. Dr. Williams specializes in treating patients with thoracic and gastrointestinal cancers, with an emphasis on nonsmall cell lung, pancreatic and hepatobiliary malignancies. Before joining City of Hope, he held several leadership roles at The James Cancer Hospital and Comprehensive Cancer Center at The Ohio State University. Dr. Williams received his M.D. and Ph.D. from Albert Einstein College of Medicine in New York and completed his residency in radiation oncology and internship in internal medicine at University of Michigan Medical Center. Before joining City of Hope, he held several leadership roles at The James Cancer Hospital and Comprehensive Cancer Center at The Ohio State University. He has a National Institutes of Health-funded research laboratory and has received numerous funding and awards from the National Cancer Institute, National Institutes of Health, American Society of Radiation Oncology, American Society of Clinical Oncology, American Cancer Society and the Radiologic Society of North America. He also serves as a permanent member of the National Institutes of Health Radiation Therapeutics and Biology study section, vice-chair of American Society for Radiation Oncology biology scientific programs, and serves on numerous committees for NRG Oncology and Alliance for Clinical Trials in Oncology. His research interests are in stereotactic body radiation therapy, experimental therapeutics, radiogenomics, DNA repair, radiobiology, nutrient scavenging and theranostics.

Modi is a dermatologist with a focus on high-risk skin cancers and melanoma and assistant clinical professor in the Division of Dermatology at City of Hope.

A widely published expert on the care of older adults with cancer and originator of the GeriOnc hashtag, Dale, the Arthur M. Coppola Family Chair in Supportive Care Medicine, co-chaired the panel that developed the 2018 ASCO Guideline for Geriatric Oncology.

For more than three decades, Matthew Loscalzo has worked tirelessly to change the culture of treatment beyond simply curing disease. He is both pioneer and innovator, seeing to the physical, mental, emotional, spiritual and social needs of patients, their loved ones and their caregivers.

As a surgeon, Jandial provides complex surgical treatment to cancer patients. As a scientist, his laboratory investigates the biology of cancer. He has authored 10 books and over 100 academic articles on surgery, neuroscience and cancer biology.

Ernest Han, M.D., Ph.D., is a gynecologic oncologist with specialized training in minimally invasive and robotic-assisted surgery, which allows operations to be performed with smaller incisions, reducing scarring, pain and recovery time.

Diana Londoño, M.D., performs open, endoscopic, laparoscopic and robotic-assisted procedures in patients with urologic cancers and disorders. A native of Mexico City, she speaks Spanish fluently.